# A Trial for Patients With Advanced/Recurrent Endometrial Cancer

> **NCT00377520** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 27 (actual)

## Conditions studied

- Neoplasms
- Neoplasms by Site
- Urogenital Neoplasms
- Genital Neoplasms, Female
- Uterine Neoplasms
- Endometrial Neoplasms
- Cancer of Endometrium
- Endometrial Cancer
- Cancer of the Endometrium
- Endometrium Cancer
- Neoplasms, Endometrial

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00377520
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2007-10
- **Final completion:** 2008-09
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2009-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00377520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00377520, "A Trial for Patients With Advanced/Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00377520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*